ArticleBMC plant biology2024
Less is more: CRISPR/Cas9-based mutations in DND1 gene enhance tomato resistance to powdery mildew with low fitness costs.
Article in BMC plant biology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Molecular Targets and Trait Innovation in CRISPR-Edited Vegetable Crops: An Up-to-Date Review (2020-2026).Plants (Basel, Switzerland) · 2026Review
- Disruption of SlCNGC18 enhances Cucumber mosaic virus resistance and drought tolerance in tomato (Solanum lycopersicum L. cv. Micro-Tom).BMC plant biology · 2026Article
- From Lab to Field: CRISPRing Major CultivatedInternational journal of molecular sciences · 2026Review
- Transcriptomic landscapes of tissue-specific color transition in eggplant reveal regulatory roles of lncRNAs and alternative splicing in anthocyanin biosynthesis.Frontiers in plant science · 2026Article
- Population genomics of Aosta Valley rye landraces reveals genetic structure and diversity patterns relevant for germplasm conservation.Frontiers in plant science · 2026Article
- Winning by Losing: Exploiting Modified Plant Susceptibility Genes to Counteract Necrotrophic Fungal Pathogens.Plant biotechnology journal · 2025Review
- The Enhancement of Fungal Disease Resistance in Major Staple Crops Using CRISPR-Cas Technology.Genes · 2025Review
- Allelic value in gene regulation-implications for gene editing.Annals of botany · 2025Article
- Powdery Mildew Caused by Leveillula taurica (Synonym: Phyllactinia taurica): A Global Challenge for Pepper Production.Molecular plant pathology · 2025Review
- Conservation and valorization of Italian potato biodiversity through genotype-by-sequencing (GBS).Frontiers in plant science · 2025Article
- Use of CRISPR Technology in Gene Editing for Tolerance to Biotic Factors in Plants: A Systematic Review.Current issues in molecular biology · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
Powdery mildew (PM), triggered by Oidium neolycopersici, represents a significant threat and a major concern for the productivity of tomato plants (Solanum lycopersicum L.). The presence of susceptibility (S) genes in plants facilitates pathogen proliferation and their dysfunction can lead to a recessively inherited broad-spectrum and durable type of resistance. Past studies have demonstrated that disrupting the function of DND1 (Defense No Death 1) increases plant resilience against various pathogens, such as powdery mildew (PM), but this comes at the cost of negatively affecting the overall health and vigor of the plant. To investigate the possibility of minimizing the adverse effects of the dnd1 mutation while boosting disease resistance, a CRISPR-Cas9 construct with four single guide RNAs targeting three exons of SlDND1 (Solyc02g088560.4.1) was designed and introduced into the tomato variety Moneymaker (MM) through Agrobacterium tumefaciens-mediated transformation. Three T
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.